{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:47:21Z","timestamp":1792090041674,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Hunan Provincial Key Laboratory of the Traditional Chinese Medicine Agricultural Biogenomi"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00520-026-11303-8","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:52:49Z","timestamp":1790855569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics, treatment and prognosis of nivolumab induced cytokine release syndrome"],"prefix":"10.1007","volume":"34","author":[{"given":"Shaoli","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"9","key":"11303_CR1","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1080\/21645515.2016.1175694","volume":"12","author":"A Rajan","year":"2016","unstructured":"Rajan A, Kim C, Heery CR, Guha U, Gulley JL (2016) Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother 12(9):2219\u20132231. https:\/\/doi.org\/10.1080\/21645515.2016.1175694","journal-title":"Hum Vaccin Immunother"},{"issue":"17","key":"11303_CR2","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33(17):1974\u20131982. https:\/\/doi.org\/10.1200\/JCO.2014.59.4358","journal-title":"J Clin Oncol"},{"issue":"4","key":"11303_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-0897-9","volume":"22","author":"EP Darnell","year":"2020","unstructured":"Darnell EP, Mooradian MJ, Baruch EN, Yilmaz M, Reynolds KL (2020) Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls. Curr Oncol Rep 22(4):39. https:\/\/doi.org\/10.1007\/s11912-020-0897-9","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"11303_CR4","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00134-017-4943-5","volume":"44","author":"P G\u00f6del","year":"2018","unstructured":"G\u00f6del P, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M (2018) Understanding cytokine release syndrome. Intensive Care Med 44(3):371\u2013373. https:\/\/doi.org\/10.1007\/s00134-017-4943-5","journal-title":"Intensive Care Med"},{"issue":"1","key":"11303_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, Stemmler HJ, Schl\u00f6\u00dfer HA, Schlaak M, Kochanek M, B\u00f6ll B, von Bergwelt-Baildon MS (2018) Cytokine release syndrome. J Immunother Cancer 6(1):56. https:\/\/doi.org\/10.1186\/s40425-018-0343-9","journal-title":"J Immunother Cancer"},{"issue":"4","key":"11303_CR6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.57730","volume":"16","author":"I Rathi","year":"2024","unstructured":"Rathi I, Mavi A, Shannawaz M, Saeed S, Yadav A, Hasan S (2024) Effectiveness of Ayurveda intervention in the management of infertility: a systematic review. Cureus 16(4):e57730. https:\/\/doi.org\/10.7759\/cureus.57730","journal-title":"Cureus"},{"issue":"4","key":"11303_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25(4):625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"key":"11303_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00557","volume":"11","author":"A Ceschi","year":"2020","unstructured":"Ceschi A, Noseda R, Palin K, Verhamme K (2020) Immune checkpoint inhibitor-related cytokine release syndrome: analysis of WHO global pharmacovigilance database. Front Pharmacol 11:557. https:\/\/doi.org\/10.3389\/fphar.2020.00557","journal-title":"Front Pharmacol"},{"key":"11303_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807050","volume":"13","author":"SH Tay","year":"2022","unstructured":"Tay SH, Toh MMX, Thian YL, Vellayappan BA, Fairhurst AM, Chan YH et al (2022) Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature. Front Immunol 13:807050. https:\/\/doi.org\/10.3389\/fimmu.2022.807050","journal-title":"Front Immunol"},{"issue":"7","key":"11303_CR10","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1172\/JCI2629","volume":"102","author":"D Fishman","year":"1998","unstructured":"Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102(7):1369\u20131376. https:\/\/doi.org\/10.1172\/JCI2629","journal-title":"J Clin Invest"},{"issue":"21","key":"11303_CR11","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130(21):2295\u20132306. https:\/\/doi.org\/10.1182\/blood-2017-06-793141","journal-title":"Blood"},{"key":"11303_CR12","doi-asserted-by":"publisher","first-page":"1508682","DOI":"10.3389\/fonc.2025.1508682","volume":"15","author":"T Otsuka","year":"2025","unstructured":"Otsuka T, Kojitani Y, Imamura F, Fukutake J, Nishio M, Fujii T, Kudo T (2025) Late-onset and relapsed cytokine release syndrome after nivolumab treatment in a patient with head and neck squamous cell carcinoma: a case report. Front Oncol 15:1508682. https:\/\/doi.org\/10.3389\/fonc.2025.1508682","journal-title":"Front Oncol"},{"issue":"3","key":"11303_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006398","volume":"11","author":"J Naidoo","year":"2023","unstructured":"Naidoo J, Murphy C, Atkins MB, Brahmer JR, Champiat S, Feltquate D et al (2023) Society for immunotherapy of cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. J Immunother Cancer 11(3):e006398. https:\/\/doi.org\/10.1136\/jitc-2022-006398","journal-title":"J Immunother Cancer"},{"issue":"4","key":"11303_CR14","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.20892\/j.issn.2095-3941.2021.0037","volume":"18","author":"W Zhang","year":"2021","unstructured":"Zhang W, Meng Y, Yang L, Shen M, Zhou L, Li R, Wang Y, Du W, Xiong Y, Han Y, Zhang X, Liu L, Ren X (2021) Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events. Cancer Biol Med 18(4):1109\u20131117. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2021.0037","journal-title":"Cancer Biol Med"},{"issue":"26","key":"11303_CR15","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127(26):3321\u20133330. https:\/\/doi.org\/10.1182\/blood-2016-04-703751","journal-title":"Blood"},{"key":"11303_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M et al (2018) Cytokine release syndrome. J Immunother Cancer 6:56. https:\/\/doi.org\/10.1186\/s40425-018-0343-9","journal-title":"J Immunother Cancer"},{"issue":"6","key":"11303_CR17","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N et al (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6(6):664\u2013679. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0040","journal-title":"Cancer Discov"},{"issue":"5","key":"11303_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1586\/eci.09.31","volume":"5","author":"PJ Bugelski","year":"2009","unstructured":"Bugelski PJ, Achuthanandam R, Capocasale RJ, Treacy G, Bouman-Thio E (2009) Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol 5(5):499\u2013521. https:\/\/doi.org\/10.1586\/eci.09.31","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"11303_CR19","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1517\/14712598.2016.1152256","volume":"16","author":"JM Ryan","year":"2016","unstructured":"Ryan JM, Wasser JS, Adler AJ, Vella AT (2016) Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: can we have our cake and eat it too? Expert Opin Biol Ther 16(5):655\u2013674. https:\/\/doi.org\/10.1517\/14712598.2016.1152256","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"11303_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001511","volume":"8","author":"MV Maus","year":"2020","unstructured":"Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML et al (2020) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer 8(2):e001511. https:\/\/doi.org\/10.1136\/jitc-2020-001511","journal-title":"J Immunother Cancer"},{"issue":"35","key":"11303_CR21","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M et al (2021) Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol 39(35):3978\u20133992. https:\/\/doi.org\/10.1200\/JCO.21.01992","journal-title":"J Clin Oncol"},{"issue":"1","key":"11303_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1158\/1078-0432.CCR-18-1379","volume":"25","author":"H Zhang","year":"2019","unstructured":"Zhang H, Meng J, Jiang Y, Deng Q, Zhao M (2019) Plasma exchange can be an alternative therapeutic modality for severe cytokine release syndrome after chimeric antigen receptor-T cell infusion: a case report. Clin Cancer Res 25(1):29\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1379","journal-title":"Clin Cancer Res"},{"issue":"4","key":"11303_CR23","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.beha.2017.09.002","volume":"30","author":"N Frey","year":"2017","unstructured":"Frey N (2017) Cytokine release syndrome: who is at risk and how to treat. Best Pract Res Clin Haematol 30(4):336\u2013340. https:\/\/doi.org\/10.1016\/j.beha.2017.09.002","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"11303_CR24","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1097\/MPH.0000000000000703","volume":"39","author":"AE Foran","year":"2017","unstructured":"Foran AE, Nadel HR, Lee AF, Savage KJ, Deyell RJ (2017) Nivolumab in the treatment of refractory pediatric Hodgkin lymphoma. J Pediatr Hematol Oncol 39(5):e263\u2013e266. https:\/\/doi.org\/10.1097\/MPH.0000000000000703","journal-title":"J Pediatr Hematol Oncol"},{"issue":"11","key":"11303_CR25","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2217\/imt-2018-0025","volume":"10","author":"L Zhao","year":"2018","unstructured":"Zhao L, Yang Y, Li W, Li T, Gao Q (2018) Nivolumab-induced cytokine-release syndrome in relapsed\/refractory Hodgkin\u2019s lymphoma: a case report and literature review. Immunotherapy (Lond) 10(11):913\u2013917. https:\/\/doi.org\/10.2217\/imt-2018-0025","journal-title":"Immunotherapy (Lond)"},{"issue":"1","key":"11303_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/iju5.12812","volume":"8","author":"T Inoue","year":"2024","unstructured":"Inoue T, Todaka A, Fuse M, Suzuki S, Sejiyama S, Ando T, Shin T (2024) Cytokine release syndrome treated with tocilizumab following ipilimumab-nivolumab combination therapy in advanced renal cell carcinoma. IJU Case Rep 8(1):64\u201368. https:\/\/doi.org\/10.1002\/iju5.12812","journal-title":"IJU Case Rep"},{"issue":"Sup1","key":"11303_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2020-142025","volume":"136","author":"R Gali","year":"2020","unstructured":"Gali R, Alejos D, Mantzaris IMS (2020) Late-onset cytokine release syndrome (CRS) in HIV patient with relapsed classical Hodgkin lymphoma on nivolumab and non-compliance with anti-retroviral therapy. Blood 136(Sup1):17. https:\/\/doi.org\/10.1182\/blood-2020-142025","journal-title":"Blood"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11303-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11303-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11303-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:48:42Z","timestamp":1792086522000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11303-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["11303"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11303-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval and consent were not required as this study was based on publicly available data.","order":1,"name":"Ethics","label":"Ethics of approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1039"}}